Primarily market-linked growth exposure
The investment objective of the scheme is to track the CRISIL-IBX 50:50 Gilt Plus SDL Index – April 2033 by investing in Government Securities (G-Sec) and SDLs, maturing on or before April, 2033 and seeks to generate returns that are commensurate (before fees and expenses) with the performance of the underlying Index, subject to tracking error. However, there is no assurance that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.
Investors with a long horizon who can tolerate meaningful falls in value.
Share-price volatility, valuation risk, concentration and tracking risk where applicable.
How the money may be invested
1. Government Securities forming part of the G-Sec portion of CRISIL-IBX 50:50 Gilt Plus SDL Index – April 2033 and State Development Loans (SDLs) forming part of the CRISIL-IBX 50:50 Gilt Plus SDL Index – April 2033 - 95% to 100% 2. Cash and Cash Equivalents - 0% to 5% For detailed asset allocation pattern, please refer to the Scheme Information Document
- SEBI category
- Index Fund
- Fund type
- An open ended target maturity index fund investing in the constituents of CRISIL-IBX 50:50 Gilt Plus SDL Index – April 2033. A relatively high interest rate risk and relatively low credit risk.
- Primary benchmark
- CRISIL-IBX 50:50 Gilt Plus SDL Index – April 2033
Use the latest monthly portfolio
Top holdings are the largest securities currently owned by the scheme. Names and weights can change every month, so a copied list can become misleading. Open the AMC's current official portfolio or factsheet below and look for this exact fund name.
Manager and scheme tenure
- Fund manager(s)
- Mr. Shantanu Godambe
- Manager tenure on this scheme
- Since Mr. Shantanu Godambe - 01/07/2023
- Role / co-management
- Mr. Shantanu Godambe - Primary
The tenure above is experience managing this scheme, not the manager's total career experience. For education, qualifications and prior roles, open the latest official AMC factsheet or manager profile below.
Latest NAV records
NAV is a per-unit accounting value. Compare returns, portfolio, risk and cost — never choose a fund only because its NAV looks low.
| Plan / option reported by AMFI | NAV | Date |
|---|---|---|
| DSP CRISIL-IBX 50:50 Gilt Plus SDL - April 2033 Index Fund - Direct Plan - Growth | ₹13.1430 | 04 Sep 2026 |
| DSP CRISIL-IBX 50:50 Gilt Plus SDL - April 2033 Index Fund - Direct Plan - IDCW | ₹13.1430 | 04 Sep 2026 |
| DSP CRISIL-IBX 50:50 Gilt Plus SDL - April 2033 Index Fund - Regular Plan - Growth | ₹13.0227 | 04 Sep 2026 |
| DSP CRISIL-IBX 50:50 Gilt Plus SDL - April 2033 Index Fund - Regular Plan - IDCW | ₹13.0227 | 04 Sep 2026 |
What you pay and how money moves
- Stated expense ratio
- Regular 0.40%, Direct 0.15%
- Exit load
- Nil
- Minimum application
- 100 · multiples of Re. 1/-
- SIP frequency
- SIP - Daily / Weekly/ Monthly / Quarterly / Half-yearly / Yearly, SWP - Weekly / Monthly / Quarterly/ Half-yearly / Yearly, STP - Daily / Weekly / Monthly / Quarterly/ Half-yearly / Yearly
- Minimum SIP amount
- SIP, SWP, STP - Rs. 100/- for all frequencies
- Minimum instalments
- SIP - Minimum 12 installments for all frequencies, SWP & STP - Minimum 6 for all frequencies
How a mutual-fund investment is paid
- Complete KYCIdentity, PAN, bank and contact verification are required.
- Choose route and optionUnderstand direct vs regular and growth vs IDCW before selecting.
- Choose SIP or lump sumSIP uses an automated mandate; lump sum is a one-time payment.
- Receive units at applicable NAVCut-off time, cleared funds and scheme rules determine the applicable NAV.
- Review, do not chaseTrack goal fit, risk, manager/mandate changes, costs and portfolio — not daily noise.
Download and verify at source
The packaged Scheme Summary PDF is the official AMFI file, unchanged. Live AMC links are included for time-sensitive factsheets, top holdings and portfolios.
Source verification date: 06 September 2026. If a live document differs from this page, rely on the newer official document.